- Home
- TAVI vs ADAP Comparison
TAVI vs ADAP Comparison
Compare TAVI & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAVI
- ADAP
- Stock Information
- Founded
- TAVI 2024
- ADAP 2008
- Country
- TAVI United Kingdom
- ADAP United Kingdom
- Employees
- TAVI N/A
- ADAP N/A
- Industry
- TAVI
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- TAVI
- ADAP Health Care
- Exchange
- TAVI Nasdaq
- ADAP Nasdaq
- Market Cap
- TAVI 158.5M
- ADAP 158.6M
- IPO Year
- TAVI 2024
- ADAP 2015
- Fundamental
- Price
- TAVI $9.97
- ADAP $0.57
- Analyst Decision
- TAVI
- ADAP Strong Buy
- Analyst Count
- TAVI 0
- ADAP 4
- Target Price
- TAVI N/A
- ADAP $2.79
- AVG Volume (30 Days)
- TAVI 10.8K
- ADAP 1.2M
- Earning Date
- TAVI 01-01-0001
- ADAP 03-05-2025
- Dividend Yield
- TAVI N/A
- ADAP N/A
- EPS Growth
- TAVI N/A
- ADAP N/A
- EPS
- TAVI N/A
- ADAP N/A
- Revenue
- TAVI N/A
- ADAP $175,041,000.00
- Revenue This Year
- TAVI N/A
- ADAP $204.91
- Revenue Next Year
- TAVI N/A
- ADAP N/A
- P/E Ratio
- TAVI N/A
- ADAP N/A
- Revenue Growth
- TAVI N/A
- ADAP 146.27
- 52 Week Low
- TAVI $9.99
- ADAP $0.53
- 52 Week High
- TAVI $10.76
- ADAP $2.05
- Technical
- Relative Strength Index (RSI)
- TAVI N/A
- ADAP 42.78
- Support Level
- TAVI N/A
- ADAP $0.57
- Resistance Level
- TAVI N/A
- ADAP $0.62
- Average True Range (ATR)
- TAVI 0.00
- ADAP 0.04
- MACD
- TAVI 0.00
- ADAP 0.00
- Stochastic Oscillator
- TAVI 0.00
- ADAP 37.33
About TAVI Tavia Acquisition Corp. Ordinary Shares
Tavia Acquisition Corp is a blank check company.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.